Celltrion Secures Deal With PBM Express Scripts For Subcutaneous Infliximab
The Agreement Gives The Drug Access To Nearly 22 Million Patients In The US
Celltrion unveils its agreement with the PBM Express Scripts that will place its Zymfentra subcutaneous infliximab on its preferred formulary after alluding to the deal in an earlier notice.
